GMED has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GMED has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Globus Medical's Enterprise Value is $8,832 Mil. Globus Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $152 Mil. Therefore, Globus Medical's EV-to-FCF for today is 58.21.
The historical rank and industry rank for Globus Medical's EV-to-FCF or its related term are showing as below:
During the past 13 years, the highest EV-to-FCF of Globus Medical was 73.73. The lowest was 14.10. And the median was 38.50.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-13), Globus Medical's stock price is $64.72. Globus Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.640. Therefore, Globus Medical's PE Ratio for today is 101.13.
The historical data trend for Globus Medical's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Globus Medical Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-FCF | Get a 7-Day Free Trial | 54.99 | 44.97 | 31.40 | 67.05 | 43.99 |
Globus Medical Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-FCF | Get a 7-Day Free Trial | 44.25 | 44.34 | 54.51 | 43.99 | 48.35 |
For the Medical Devices subindustry, Globus Medical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Globus Medical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Globus Medical's EV-to-FCF falls into.
Globus Medical's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 8832.044 | / | 151.722 | |
= | 58.21 |
Globus Medical's current Enterprise Value is $8,832 Mil.
Globus Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $152 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Globus Medical (NYSE:GMED) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Globus Medical's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 64.72 | / | 0.640 | |
= | 101.13 |
Globus Medical's share price for today is $64.72.
Globus Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.640.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Globus Medical's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Leslie V Norwalk | director | C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130 |
Dan Wolterman | director | 3721 VALLEY CENTRE DR, SUITE 500, SAN DIEGO CA 92130 |
John A Deford | director | C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
Dan Lemaitre | director | 2 MUSICK, IRVINE CA 92618 |
Keith W Pfeil | officer: SVP, Chief Financial Officer | GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403 |
Kelly Huller | officer: SVP, General Counsel | 2560 GENERAL ARMISTEAD AVENUE, AUDOBON PA 19403 |
David D Davidar | director, officer: Vice President, Operations | C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403 |
James R Tobin | director | C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Daniel T Scavilla | officer: Senior VP and CFO | C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403 |
David M Demski | director, officer: President and COO | C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403 |
Robert Andrew Douglas | director | 21 ATTUNGA ROAD, NEWPORT, NEW SOUTH WALES C3 2106 |
Stephen T Zarrilli | director | FIBERLINK COMMUNICATIONS CORP., 794 PENLLYN PIKE, BLUE BELL PA 19422 |
Anthony L Williams | officer: Senior VP of Bus. Devel. & GC | C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403 |
Steven Payne | officer: Chief Accounting Officer | C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403 |
David C Paul | director, 10 percent owner, officer: Chief Executive Officer | C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-17-2022
By sperokesalga sperokesalga • 03-19-2023
By GlobeNewswire GlobeNewswire • 04-19-2023
By Marketwired • 07-31-2023
By sperokesalga sperokesalga • 02-12-2023
By Marketwired • 08-03-2023
By Marketwired • 10-24-2023
By GuruFocusNews GuruFocusNews • 06-07-2022
By PurpleRose PurpleRose • 07-18-2022
By Marketwired • 09-27-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.